Company: SWKH
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001628280-25-025955
Chunk: 16

Company: SWK Holdings Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
:Interest, accounts receivable and other receivables(1,200)(1,623)Foreign currency forward contract409 (870)Other assets980 (283)Accounts payable, accrued expenses, and other non-current liabilities(872)(1,189)Deferred income1,849 1,500 Net cash provided by operating activities8,280 4,430 Cash flows from investing activities:Proceeds from sale of property and equipment110 — Sale of marketable investments— 258 Investment in finance receivables(10,000)(446)Repayment of finance receivables32,684 9,362 Corporate debt securities principal payments8 7 Purchases of property and equipment(100)— Net cash provided by investing activities22,702 9,181 Cash flows from financing activities:Net payments on credit facility(6,233)(12,350)Repurchases of common stock, including fees and expenses(867)(999)Net cash used in financing activities(7,100)(13,349)Net increase in cash and cash equivalents23,882 262 Cash and cash equivalents at beginning of period5,927 5,236 Cash and cash equivalents at end of period$29,809 $5,498 Supplemental non-cash investing and financing activities:Transfer of finance receivables and related interest receivable to held for sale$33,990 $— Cash paid for interest$775 $173 Fair value of warrants received with investment in finance receivables$253 $— 

See accompanying notes to the unaudited condensed consolidated financial statements.

4

SWK HOLDINGS CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies

Nature of Operations SWK Holdings Corporation (the “Company,” “we,” or “us”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology,